Nuclear Pharmacy - Global Strategic Business Report

The global market for Nuclear Pharmacy was valued at US$6.1 Billion in 2025 and is projected to reach US$9.5 Billion by 2032, growing at a CAGR of 6.6% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Nuclear Pharmacy Market - Key Trends & Drivers Summarized

Why Is Nuclear Pharmacy Gaining Prominence in Modern Healthcare?

Nuclear pharmacy is emerging as a critical component of diagnostic and therapeutic medicine due to its role in preparing radiopharmaceuticals used in nuclear imaging and targeted treatments. As demand rises for precision diagnostics in oncology, cardiology, and neurology, nuclear pharmacies are becoming essential in supplying time-sensitive, patient-specific radiotracers to imaging centers and hospitals. These compounds help visualize biological processes at the molecular level, enabling early detection of disease and more accurate monitoring of treatment response.

In addition to diagnostic imaging, nuclear pharmacy plays a growing role in theranostics - where therapeutic and diagnostic capabilities are combined in a single radiopharmaceutical. This integration supports a more personalized approach to patient care, where specific isotopes can be used to both identify and treat tumors. As healthcare shifts toward minimally invasive and targeted interventions, nuclear pharmacy is expected to play an increasingly central role in clinical workflows.

How Are Advancements in Radiopharmaceuticals and Isotope Production Driving Growth?

The development of new radiopharmaceuticals is expanding the scope of nuclear pharmacy beyond conventional tracers such as technetium-99m and fluorine-18. Novel agents are being designed for more specific disease targeting, including peptides and antibodies labeled with isotopes like lutetium-177 and gallium-68. These compounds are being used in the management of prostate cancer, neuroendocrine tumors, and other hard-to-treat conditions, creating opportunities for specialized nuclear pharmacy operations.

Isotope production is also undergoing transformation. Cyclotron and generator-based production techniques are improving reliability and local availability of short-lived isotopes, reducing dependency on aging nuclear reactors. Automated synthesis modules and quality control systems are improving radiopharmaceutical preparation, standardizing dosage, and reducing exposure risks to pharmacy personnel. These innovations are supporting faster, safer, and more scalable delivery of radiotracers to healthcare providers.

What Structural and Regulatory Factors Influence Market Expansion?

Nuclear pharmacy operates under strict regulatory controls given the handling of radioactive materials. Compliance with national and international standards requires specialized infrastructure, staff training, and licensing, which limits the number of facilities that can operate at scale. However, growth in centralized and networked radiopharmacies is helping healthcare systems improve logistics, reduce waste, and ensure on-time delivery of radiopharmaceuticals with short half-lives.

The rise of outpatient diagnostic centers and integrated care networks is further influencing nuclear pharmacy expansion. Many health systems are investing in in-house or partnered radiopharmacy capabilities to reduce reliance on external suppliers. Public and private funding in cancer care, coupled with regulatory fast-tracking of novel radiotherapeutics, is strengthening supply chains and accelerating market development. Partnerships between pharmaceutical companies, isotope producers, and healthcare providers are also emerging to meet rising clinical demand.

Growth in the nuclear pharmacy market is driven by several factors.

Increased use of nuclear imaging and theranostics in oncology, cardiology, and neurology is boosting demand for timely, high-quality radiopharmaceuticals. Development of novel isotopes and targeted radiotracers is expanding the range of clinical applications. Advances in automated synthesis and isotope production technologies are improving operational efficiency and safety. Expansion of centralized radiopharmacy models is enabling wider access to time-sensitive diagnostic agents. Regulatory support for new radiotherapeutics and growing investment in personalized medicine are reinforcing the integration of nuclear pharmacy into standard care protocols. These factors are collectively shaping a strong growth trajectory for the nuclear pharmacy market globally.

Report Scope

The report analyzes the Nuclear Pharmacy market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Type (Institutional Type, Commercial Type); Purpose (Diagnostic, Therapeutic)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Institutional Type segment, which is expected to reach US$5.3 Billion by 2032 with a CAGR of a 5.2%. The Commercial Type segment is also set to grow at 8.4% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $1.7 Billion in 2025, and China, forecasted to grow at an impressive 9.8% CAGR to reach $2.0 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Nuclear Pharmacy Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Nuclear Pharmacy Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Nuclear Pharmacy Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Advanced Accelerator Applications (AAA), Bayer AG (Radiopharma division), Bracco Imaging S.p.A., Cardinal Health, Inc. (Nuclear Pharmacy), Curium Pharma and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Nuclear Pharmacy market report include:

• Advanced Accelerator Applications (AAA)
• Bayer AG (Radiopharma division)
• Bracco Imaging S.p.A.
• Cardinal Health, Inc. (Nuclear Pharmacy)
• Curium Pharma
• Eczacibasi-Monrol Nuclear Products
• Eckert & Ziegler (Radiopharma division)
• GE HealthCare (Nuclear Pharmacy Services)
• IBA Molecular Imaging
• Jubilant Radiopharma (Jubilant DraxImage)
• Lantheus Medical Imaging, Inc.
• Mallinckrodt plc. (Nuclear Imaging)
• NTP Radioisotopes SOC Ltd.
• Nihon Medi-Physics Co., Ltd.
• Nordion Inc. (Sotera Health)
• Novartis (Advanced Accelerator Applications)
• PharmaLogic Holdings Corp.
• Siemens Healthineers
• Shine Technologies (SHINE Medical)
• Telix Pharmaceuticals Limited

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.